LENZ Therapeutics Files 8-K
Ticker: LENZ · Form: 8-K · Filed: Oct 28, 2024 · CIK: 1815776
| Field | Detail |
|---|---|
| Company | Lenz Therapeutics, Inc. (LENZ) |
| Form Type | 8-K |
| Filed Date | Oct 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
LENZ Therapeutics filed an 8-K, standard corporate update.
AI Summary
LENZ Therapeutics, Inc. filed an 8-K on October 28, 2024, reporting other events and financial statements. The company, formerly known as Graphite Bio, Inc. and Integral Medicines, Inc., is incorporated in Delaware and headquartered in Solana Beach, California.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate events and financial statements, not indicating any specific material changes or risks.
Key Numbers
- 001-40532 — SEC File Number (Identifies the company's filing with the SEC)
- 84-4867570 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- LENZ Therapeutics, Inc. (company) — Registrant
- Graphite Bio, Inc. (company) — Former company name
- Integral Medicines, Inc. (company) — Former company name
- October 27, 2024 (date) — Date of earliest event reported
- October 28, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for LENZ Therapeutics, Inc.?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 27, 2024.
When was the report filed with the SEC?
The report was filed on October 28, 2024.
What were LENZ Therapeutics, Inc.'s former company names?
LENZ Therapeutics, Inc. was formerly known as Graphite Bio, Inc. and Integral Medicines, Inc.
Where is LENZ Therapeutics, Inc. headquartered?
LENZ Therapeutics, Inc. is headquartered at 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, California, 92075.
What is the SIC code for LENZ Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for LENZ Therapeutics, Inc. is 2836, which pertains to Biological Products (No Diagnostic Substances).
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-10-28 08:09:55
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share LENZ The Nasdaq Stock Market
Filing Documents
- lenz-20241027.htm (8-K) — 27KB
- exhibit991-jixingdataannou.htm (EX-99.1) — 23KB
- corxellogo.jpg (GRAPHIC) — 3KB
- lenzlogo.jpg (GRAPHIC) — 3KB
- 0001815776-24-000064.txt ( ) — 193KB
- lenz-20241027.xsd (EX-101.SCH) — 2KB
- lenz-20241027_lab.xml (EX-101.LAB) — 23KB
- lenz-20241027_pre.xml (EX-101.PRE) — 13KB
- lenz-20241027_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 27, 2024, LENZ Therapeutics, Inc. and Corxel Pharmaceuticals issued a joint press release announcing topline data from the Phase 3 JX07001 clinical trial of LNZ100 in patients with presbyopia in China. The press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated October 2 7 , 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LENZ THERAPEUTICS, INC. Dated: October 27, 2024 By: /s/ Daniel Chevallard Name: Daniel Chevallard Title: Chief Financial Officer (Principal Financial and Accounting Officer)